Skip to main content

Table 2 Detection of individual high-risk and low-risk HPV genotypes by CLART and LA in 401 women with abnormal cytology

From: Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study

Genotype Prevalence Agreement
CLART, N (%) LA, N (%) Relative prevalence CLART vs. LA (95% CI) CLART+/LA+ CLART+/LA- CLART-/LA+ CLART-/LA- Total agreement (95% CI) Positive agreement (95% CI)
High-risk          
16 121 (30%) 126 (31%) 0.96 (0.78-1.18) 120 (30%) 1 (0%) 6 (1%) 274 (68%) 98% (96-99) 94% (89-98)
18 45 (11%) 53 (13%) 0.85 (0.59-1.23) 45 (11%) 0 (0%) 8 (2%) 348 (87%) 98% (96-99) 85% (72-93)
31 64 (16%) 61 (15%) 1.05 (0.76-1.45) 61 (15%) 3 (1%) 0 (0%) 337 (84%) 99% (98-100) 95% (87-99)
33 42 (10%) 40 (10%) 1.05 (0.70-1.58) 39 (10%) 3 (1%) 1 (0%) 358 (89%) 99% (97-100) 91% (78-97)
35 19 (5%) 16 (4%) 1.19 (0.62-2.28) 16 (4%) 3 (1%) 0 (0%) 382 (95%) 99% (98-100) 84% (60-97)
39 22 (5%) 48 (12%) 0.46 (0.28-0.74) 22 (5%) 0 (0%) 26 (6%) 353 (88%) 94% (91-96) 46% (31-61)
45 16 (4%) 35 (9%) 0.46 (0.26-0.81) 16 (4%) 0 (0%) 19 (5%) 366 (91%) 95% (93-97) 46% (29-63)
51 47 (12%) 50 (12%) 0.94 (0.65-1.37) 46 (11%) 1 (0%) 4 (1%) 350 (87%) 99% (97-100) 90% (79-97)
52 49 (12%) 40 (10%) 1.23 (0.83-1.82) 33 (8%) 16 (4%) 7 (2%) 345 (86%) 94% (92-96) 59% (45-72)
56 30 (7%) 39 (10%) 0.77 (0.49-1.21) 27 (7%) 3 (1%) 12 (3%) 359 (90%) 96% (94-98) 64% (48-78)
58 59 (15%) 40 (10%) 1.48 (1.01-2.15) 38 (9%) 21 (5%) 2 (0%) 340 (85%) 94% (92-96) 62% (49-74)
59 27 (7%) 29 (7%) 0.93 (0.56-1.54) 20 (5%) 7 (2%) 9 (2%) 365 (91%) 96% (94-98) 56% (38-72)
68 25 (6%) 16 (4%) 1.56 (0.85-2.88) 6 (1%) 19 (5%) 10 (2%) 366 (91%) 93% (90-95) 17% (7-34)
Low-risk          
6 15 (4%) 13 (3%) 1.15 (0.56-2.39) 12 (3%) 3 (1%) 1 (0%) 385 (96%) 99% (97-100) 75% (48-93)
11 4 (1%) 4 (1%) 1.00 (0.25-3.97) 4 (1%) 0 (0%) 0 (0%) 397 (99%) 100% (99-100) 100% (40-100)
26 3 (1%) 3 (1%) 1.00 (0.20-4.93) 3 (1%) 0 (0%) 0 (0%) 398 (99%) 100% (99-100) 100% (29-100)
40 5 (1%) 6 (1%) 0.83 (0.26-2.71) 5 (1%) 0 (0%) 1 (0%) 395 (99%) 100% (99-100) 83% (36-100)
42 20 (5%) 28 (7%) 0.71 (0.41-1.25) 20 (5%) 0 (0%) 8 (2%) 373 (93%) 98% (96-99) 71% (51-87)
53 50 (12%) 52 (13%) 0.96 (0.67-1.38) 48 (12%) 2 (0%) 4 (1%) 347 (87%) 99% (97-99) 89% (77-96)
54 15 (4%) 36 (9%) 0.42 (0.23-0.75) 14 (3%) 1 (0%) 22 (5%) 364 (91%) 94% (92-96) 38% (22-55)
61 34 (8%) 44 (11%) 0.77 (0.50-1.18) 34 (8%) 0 (0%) 10 (2%) 357 (89%) 98% (95-99) 77% (62-89)
62 12 (3%) 30 (7%) 0.40 (0.21-0.77) 12 (3%) 0 (0%) 18 (4%) 371 (93%) 96% (93-97) 40% (23-59)
66 44 (11%) 40 (10%) 1.10 (0.73-1.65) 37 (9%) 7 (2%) 3 (1%) 354 (88%) 98% (95-99) 79% (64-89)
70 28 (7%) 24 (6%) 1.17 (0.69-1.98) 24 (6%) 4 (1%) 0 (0%) 373 (93%) 99% (97-100) 86% (67-96)
71 1 (0% 2 (0%) 0.50 (0.05-5.49) 0 (0%) 1 (0%) 2 (0%) 398 (99%) 99% (98-100) 0% (0-71)
72 1 (0%) 1 (0%) 1.00 (0.06-15.93) 1 (0%) 0 (0%) 0 (0%) 400 (100%) 100% (99-100) 100% (3-100)
73 11 (3%) 31 (8%) 0.35 (0.18-0.70) 11 (3%) 0 (0%) 20 (5%) 370 (92%) 95% (92-97) 35% (19-55)
81 12 (3%) 14 (3%) 0.86 (0.40-1.83) 12 (3%) 0 (0%) 2 (0%) 387 (97%) 100% (98-100) 86% (57-98)
82 47 (12%) 21 (5%) 2.24 (1.36-3.67) 20 (5%) 27 (7%) 1 (0%) 353 (88%) 93% (90-95) 42% (28-57)
83 15 (4%) 14 (3%) 1.07 (0.52-2.19) 12 (3%) 3 (1%) 2 (0%) 384 (96%) 99% (97-100) 71% (44-90)
84 15 (4%) 26 (6%) 0.58 (0.31-1.07) 15 (4%) 0 (0%) 11 (3%) 375 (94%) 97% (95-99) 58% (37-77)